Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 111-119 , April 2011

Malignant pheochromocytomas and paragangliomas – The importance of a multidisciplinary approach

  • Kim Francis Andersen

      Affiliations

    • Department of Clinical Physiology and Nuclear Medicine, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 44883408; fax: +45 44883411.
    • ,
  • Rahim Altaf

      Affiliations

    • Department of Oncology, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Tel.: +45 44884488.
    • ,
  • Anders Krarup-Hansen

      Affiliations

    • Department of Oncology, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Tel.: +45 44884488.
    • ,
  • Bjarne Kromann-Andersen

      Affiliations

    • Department of Urology, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Tel.: +45 44884488.
    • ,
  • Thomas Horn

      Affiliations

    • Department of Pathology, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Tel.: +45 44884488.
    • ,
  • Niels Juel Christensen

      Affiliations

    • Department of Endocrinology and Internal Medicine, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Tel.: +45 44884488.
    • ,
  • Helle Westergren Hendel

      Affiliations

    • Department of Clinical Physiology and Nuclear Medicine, Herlev Hospital, University Hospital of Copenhagen, DK-2730 Herlev, Denmark
    • Tel.: +45 44884488.

Received 14 February 2010 ,Revised 6 July 2010 ,Accepted 8 July 2010.

References 

  1. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE. The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977–1981. J Hum Hypertens. 1988;2(3):187–189
  2. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950–1979. Mayo Clin Proc. 1983;58(12):802–804
  3. deGraeff J, Horak BJV. The incidence of pheochromocytoma in the Netherlands. Acta Med Scand. 1964;(176):583–593
  4. Fernandez-Calvet L, Garcia-Mayor RV. Incidence of pheochromocytoma in South Galicia, Spain. J Intern Med. 1994;236(6):675–677
  5. Hartley L, Perry-Keene D. Phaeochromocytoma in Queensland 1970–1983. Aust NZ J Surg. 1985;55(5):471–475
  6. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet. 2002;39(9):617–622
  7. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86(11):5210–5216
  8. Oosterwijk JC, Jansen JC, van Schothorst EM, Oosterhof AW, Devilee P, Bakker E, et al. First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas). J Med Genet. 1996;33(5):379–383
  9. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(3):569–585
  10. Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery. 2008;143(6):759–768
  11. Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, et al. National cancer data base report on malignant paragangliomas of the head and neck. Cancer. 2002;94(3):730–737
  12. Jimenez C, Cote G, Arnold A, Gagel RF. Review: should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?. J Clin Endocrinol Metab. 2006;91(8):2851–2858
  13. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacche M, Mori L, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or non-functional paragangliomas. J Clin Endocrinol Metab; February 17, 2009.
  14. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the first international symposium. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102
  15. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92(3):779–786
  16. Santarpia L, Habra MA, Jimenez C. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Horm Metab Res. 2009;41(9):680–686
  17. Erlic Z, Neumann HP. When should genetic testing be obtained in a patient with phaeochromocytoma or paraganglioma?. Clin Endocrinol (Oxf). 2009;70(3):354–357
  18. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94(8):2817–2827
  19. Erlic Z, Neumann HP. Diagnosing patients with hereditary paraganglial tumours. Lancet Oncol. 2009;10(8):741
  20. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res. 2008;40(5):329–337
  21. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002;287(11):1427–1434
  22. Rao F, Keiser HR, O’Connor DT. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension. 2000;36(6):1045–1052
  23. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505–4509
  24. Grossman A, Pacak K, Sawka A, Lenders JW, Harlander D, Peaston RT, et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?. Ann NY Acad Sci. 2006;1073:332–347
  25. van der Harst E, de Herder WW, De Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol. 2002;147(1):85–94
  26. Amar L, Peyrard S, Rossignol P, Zinzindohoue F, Gimenez-Roqueplo AP, Plouin PF. Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas. Ann NY Acad Sci. 2006;1073:383–391
  27. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O’Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med. 1990;88(6):607–613
  28. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, de Herder WW, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82(8):2622–2628
  29. Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M, Baudin E. Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer. 2001;84(6):808–812
  30. Portel-Gomes GM, Grimelius L, Johansson H, Wilander E, Stridsberg M. Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am J Surg Pathol. 2001;25(10):1261–1267
  31. Giovanella L, Squin N, Ghelfo A, Ceriani L. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging. 2006;50(4):344–347
  32. Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf). 2006;65(3):287–293
  33. Moreno AM, Castilla-Guerra L, Martinez-Torres MC, Torres-Olivera F, Fernandez E, Galera-Davidson H. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides. 1999;33(2):159–163
  34. Oishi S, Sato T. Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma. Cancer. 1988;61(6):1167–1170
  35. Guillemot J, Barbier L, Thouennon E, Vallet-Erdtmann V, Montero-Hadjadje M, Lefebvre H, et al. Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas. Ann NY Acad Sci. 2006;1073:527–532
  36. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551–566
  37. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de KR, van NF, et al. Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score. Am J Surg Pathol. 2009;33(4):599–608
  38. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004;89(2):479–491
  39. Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am. 2007;21(3):509–525
  40. Go AS. Refining probability: an introduction to the use of diagnostic tests. In:  Friedland DJ editors. Evidence-based medicine. New York, NY: McGraw-Hill; 1998;p. 11–33
  41. Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol. 2008;35(Suppl 1):S27–S34
  42. Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann NY Acad Sci. 2006;1073:449–464
  43. Kaltsas GA, Mukherjee JJ, Foley R, Britton KE, Grossman AB. Treatment of metastatic pheochromocytoma and paraganglioma with 131I-meta-iodobenzylguanidine (MIBG). Endocrinologist. 2003;13(4):321–333
  44. van der Horst-Schrivers AN, Jager PL, Boezen HM, Schouten JP, Kema IP, Links TP. Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas – experience and meta-analysis. Anticancer Res. 2006;26(2B):1599–1604
  45. Cleary S, Phillips JK. The norepinephrine transporter and pheochromocytoma. Ann NY Acad Sci. 2006;1073:263–269
  46. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88(9):4083–4087
  47. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262–2269
  48. Guillermet-Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. J Endocrinol Invest. 2005;28(11 Suppl Int):5–9
  49. Hofland LJ, Liu Q, van Koetsveld PM, Zuijderwijk J, van der HF, De Krijger RR, et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab. 1999;84(2):775–780
  50. Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, et al. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?. Ann NY Acad Sci. 2006;1073:491–497
  51. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88(11):5150–5157
  52. Pawlikowski M. Somatostatin analogs in diagnostics and therapy. 1st ed.. Austin: Landes Bioscience; 2007;
  53. Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 1992;74(5):1082–1089
  54. Bustillo A, Telischi F, Weed D, Civantos F, Angeli S, Serafini A, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114(3):434–440
  55. Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44(11):1767–1774
  56. Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2002;29(12):1571–1580
  57. Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg. 2000;122(3):358–362
  58. van der HE, de Herder WW, Bruining HA, Bonjer HJ, De Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685–693
  59. Whiteman ML, Serafini AN, Telischi FF, Civantos FJ, Falcone S. 111In octreotide scintigraphy in the evaluation of head and neck lesions. AJNR Am J Neuroradiol. 1997;18(6):1073–1080
  60. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET – initial results. Radiology. 2002;222(2):507–512
  61. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613–1619
  62. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49(4):573–586
  63. Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156(4):483–487
  64. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33(6):1125–1131
  65. Shulkin BL, Thompson NW, Shapiro B, Sisson JC. PET epinephrine studies of pheochromocytoma. J Nucl Med. 1995;36(Suppl):22–23
  66. Trampal C, Engler H, Juhlin C, Bergstrom M, Langstrom B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology. 2004;230(2):423–428
  67. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617–1626
  68. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–1757
  69. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5(1):42–48
  70. Benn DE, Richardson AL, Marsh DJ, Robinson BG. Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann NY Acad Sci. 2006;1073:104–111
  71. Machens A, Brauckhoff M, Gimm O, Dralle H. Risk-oriented approach to hereditary adrenal pheochromocytoma. Ann NY Acad Sci. 2006;1073:417–428
  72. Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009;41(9):687–696
  73. Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for therapy?. Semin Surg Oncol. 1989;5(6):414–419
  74. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236(4):397–406
  75. Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol. 2004;5(9):550–560
  76. Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol. 2009;100(8):635–638
  77. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000;190(4):432–445
  78. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg. 1998;187(1):88–92
  79. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg. 1996;20(7):908–914
  80. Jaeck D, Oussoultzoglou E, Bachellier P, Lemarque P, Weber JC, Nakano H, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2001;25(6):689–692
  81. Nave H, Mossinger E, Feist H, Lang H, Raab H. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129(2):170–175
  82. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–581
  83. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37
  84. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005;241(5):776–783
  85. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26(8):985–990
  86. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg. 2008;32(5):930–938
  87. Veenendaal LM, Borel Rinkes IH, Lips CJ, van HR. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol. 2006;4:35
  88. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8(2):208–212
  89. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;225(4):355–364
  90. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66(10):1307–1312
  91. Bravo EL. Pheochromocytoma: an approach to antihypertensive management. Ann NY Acad Sci. 2002;970:1–10
  92. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12(4):683–699
  93. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann NY Acad Sci. 2006;1073:465–490
  94. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):62S–66S
  95. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van EM, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–2130
  96. Teunissen JJ, Kwekkeboom DJ, de Jong M, Valkema R, Krenning EP. Peptide receptor radionuclide therapy. In:  Biersack H-J,  Freeman LM editor. Clinical Nuclear Medicine. 1st ed.. Berlin, New York: Heidelberg; 2007;p. 443–455
  97. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10(4):239–253
  98. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–422
  99. Baum RP, Söldner J, Schmüching M, Niesen A. Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Der Onkologe. 2004;10(10):1098–1110
  100. Baum RP, Söldner J, Schmüching M, Niesen A. Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med. 2004;31(Suppl 2):238
  101. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30(2):207–216
  102. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754–2762
  103. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–1447
  104. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32(2):148–155
  105. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12(7):941–945
  106. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 74GBq (90)Y-DOTATOC. J Nucl Med. 2002;43(5):610–616
  107. Waldherr C, Schumacher T, Maecke HR. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?. Eur J Nucl Med. 2002;29:100–102
  108. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109(4):267–273
  109. Edstrom EE, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 2003;29(3):278–283
  110. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113(8):2020–2028
  111. Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension. 1985;7(3 Pt 2):I18–I24
  112. Naoi Y, Tamaki Y, Ooka M, Tsukamoto F, Miyoshi Y, Tanji Y, et al. A case of metastatic pheochromocytoma with remarkable response to combination of cyclophosphamide, vincristine and dacarbazine. Gan To Kagaku Ryoho. 2003;30(1):145–149
  113. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986–2991
  114. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab. 2009;94(1):5–9
  115. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, et al. Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol. 2009;39(5):327–331
  116. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24(3):401–406
  117. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41(9):697–702
  118. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets. 2003;3(5):377–383
  119. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822–3828
  120. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: implications for therapy. Ann NY Acad Sci. 2006;1073:505–511

PII: S0305-7372(10)00110-6

doi: 10.1016/j.ctrv.2010.07.002

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 111-119 , April 2011

Article Tools

* Image Usage & Resolution